NuVision

OverviewSuggest Edit

NuVision is a biotechnology research and development spin-out company. It develops ophthalmic therapies designed to address key clinical challenges and provide solutions to sight-saving problems.
TypePrivate
Founded2015
Websitenu-vision.co.uk

Latest Updates

Employees (est.) (Apr 2020)18

Key People/Management at NuVision

Mark Treherne

Mark Treherne

Chairman
Peter Dines

Peter Dines

Executive Director
Jonathan Hamill-Keays

Jonathan Hamill-Keays

Sales & Marketing Director
Andrew Hopkinson

Andrew Hopkinson

CEO
Show more

NuVision Financials and Metrics

Summary Metrics

Founding Date

2015

NuVision total Funding

$3 m

NuVision latest funding size

$1.73 m

Time since last funding

7 months ago

NuVision investors

NuVision's latest funding round in September 2019 was reported to be $1.7 m. In total, NuVision has raised $3 m
Show all financial metrics

NuVision Revenue

Cash (31-Mar-2019)

46.2k
GBPFY, 2016FY, 2017FY, 2018FY, 2019

Cash

120.1k9.7k276.6k46.2k

Accounts Receivable

99.0131.2k419.035.5k

Inventories

15.0k21.8k33.0k34.3k

Current Assets

243.6k272.7k460.4k229.5k
Y, 2019

Financial Leverage

2 x
Show all financial metrics

NuVision Online and Social Media Presence

Embed Graph

NuVision Frequently Asked Questions

  • When was NuVision founded?

    NuVision was founded in 2015.

  • Who are NuVision key executives?

    NuVision's key executives are Mark Treherne, Peter Dines and Jonathan Hamill-Keays.

  • How many employees does NuVision have?

    NuVision has 18 employees.

  • Who are NuVision competitors?

    Competitors of NuVision include Immune Therapeutics, Catalyst Pharmaceuticals and Sorrento Therapeutics.